Establishment and Characterization of a Cell Line, MT-213-VGH, Isolated from a Mixed Müllerian Tumor of the Uterus

Comparing paclitaxel-platinum with ifosfamide-platinum as the front-line chemotherapy for patients with advanced-stage uterine carcinosarcoma

“…During a median follow-up of 60 months, the authors found the best outcomes (PFS = 35 months, 95 % CI, 0.26-0.43; OS = 47 months, 95 % CI, 0.38-0.56) in women treated with IP. 49 However, recent evidence supports that UCS is various forms of poorly differentiated uterine carcinomas, 1,2,13,17,29–32 contributing to the reconsideration of the use of paclitaxel in place of ifosfamide for UCS. 35,36…”

“…During a median follow-up of 60 months, the authors found the best outcomes (PFS = 35 months, 95 % CI, 0.26-0.43; OS = 47 months, 95 % CI, 0.38-0.56) in women treated with IP. 49 However, recent evidence supports that UCS is various forms of poorly differentiated uterine carcinomas, 1,2,13,17,[29][30][31][32] contributing to the reconsideration of the use of paclitaxel in place of ifosfamide for UCS. 35,36 Powell et al 35 conducted a single-arm phase II GOG-232B trial to evaluate the efficacy of PP for recurrent or metastatic UCS to obtain 13% and 41%, of compete and partial response rates, respectively, in 55 advanced UCS (stage III and IV) patients.…”

“…7–10 Recently, clinical, pathologic, and biological evidence has indicated that UCS is a monoclonal origin, which is derived from the Müllerian duct and closely related to high-grade endometrial carcinoma with the driving force to result in sarcomatous transformation (metaplastic carcinoma), and subsequently form the homologous or heterologous groups, depending on the characteristics of the stroma or mesenchymal components of endometrial tissues. 11–13…”

“…[7][8][9][10] Recently, clinical, pathologic, and biological evidence has indicated that UCS is a monoclonal origin, which is derived from the Müllerian duct and closely related to high-grade endometrial carcinoma with the driving force to result in sarcomatous transformation (metaplastic carcinoma), and subsequently form the homologous or heterologous groups, depending on the characteristics of the stroma or mesenchymal components of endometrial tissues. [11][12][13] Primary complete surgical staging or primary cytoreductive surgery (PCS) is a key factor in the management of women with UCS, based on the studies obtained from the experience for high-grade or advanced endometrial cancer and uterine sarcomas as well as epithelial ovarian cancer, primary peritoneal serous carcinoma, and primary fallopian tube cancers. 10,14-21 PCS includes a total hysterectomy, bilateral salpingo-oophorectomy,…”